by John Cook on Sep 10, 2026 at 9:34 am September 10, 2026 at 9:35 am
Seattle biotech startup BrainChild Bio has raised $116 million to advance an experimental CAR T cell therapy for one of the deadliest forms of childhood brain cancer.
The Series A financing will primarily fund a pivotal Phase 2 clinical trial of an investigational therapy being developed for diffuse intrinsic pontine glioma, or DIPG. The rare brainstem tumor primarily affects children ages 5 to 10 and has few treatment options.
The financing was led by an undisclosed private family fund and foundation, with participation from BrainChild Bio’s initial investor, Seattle…
Read the full article at GEEKWIRE.COM


